Mounjaro vs Zepbound
Same tirzepatide molecule, split by label between diabetes and weight management.
| Attribute | Mounjaro | Zepbound |
|---|---|---|
| Molecule | Tirzepatide | Tirzepatide |
| Mechanism | Dual GIP and GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Frequency | Once weekly injection | Once weekly injection |
| Format | Prefilled single-dose pen | Prefilled single-dose pen |
| Monthly price (CAD) | $280–550/mo by dose | $435–550/mo by dose |
| Approval / indication in Canada | Type 2 diabetes management | Chronic weight management |
| Availability | Widely stocked, most pharmacies | Approved May 2025, availability expanding |
One molecule, one manufacturer, two labels
Mounjaro and Zepbound are the tirzepatide version of the split we see between Ozempic and Wegovy: the same active ingredient, made by the same company, Eli Lilly, sold under two different brand names for two different approved uses. Mounjaro carries Health Canada's approval for type 2 diabetes management. Zepbound, approved in May 2025, carries the approval for chronic weight management. The dosing mechanics and injection routine are essentially the same drug delivered under a different name and a different regulatory purpose.
As with the semaglutide pair, this split has more to do with how each product was filed and studied for approval than with any meaningful difference in what's in the pen. A patient prescribed Mounjaro off-label for weight management and one prescribed Zepbound on-label are, pharmacologically, taking the same medication.
Pricing tiers on both sides
Both products are priced in dose tiers rather than a flat monthly rate. Mounjaro's Canadian list pricing runs from roughly $280 at the lowest starting doses up toward $550 at the highest maintenance doses, following Eli Lilly's tiered structure introduced at the end of 2025. Zepbound follows a similar tiered logic, generally landing between about $435 and $550 depending on dose. At the higher end, the two converge closely in price; the more meaningful gap tends to show up at the lower, starting-dose tiers, where Mounjaro's diabetes-oriented pricing can undercut Zepbound's weight-management pricing by a wider margin.
Lilly's two different savings programs
Eli Lilly runs distinct savings mechanisms for each product, and the eligibility details matter more than the headline numbers suggest. The myMounjaro savings card can bring eligible patients' cost down to around $185 a month. Separately, the LillyConnect copay program can lower a patient's out-of-pocket cost to as little as a $25 copay — but that program is specifically restricted to patients who already have private insurance; it isn't available to patients paying entirely out of pocket or relying solely on a public plan. That eligibility line is easy to miss and worth confirming directly, since it determines whether the lowest advertised price is actually reachable for a given patient.
Coverage follows the label, even though the drug is identical
The insurance logic here mirrors the semaglutide pair almost exactly. Because Mounjaro is filed under a diabetes indication, it tends to slot into formulary categories that private and, for diabetes patients, some public coverage already recognizes. Zepbound, filed under weight management, runs into the same structural gap every weight-management GLP-1 faces in Canada: no provincial public plan reimburses it for that indication, and only a minority of employer plans, roughly 31%, cover it at all. A patient with a diabetes diagnosis who could reasonably be prescribed either drug may find the Mounjaro pathway simply better supported by their existing coverage, independent of any difference in the medication itself, since there isn't one.
The verdict: questions to ask your doctor
Because the molecule is identical, the more productive question for a doctor is which label and which coding path fits your actual diagnosis, since that determines both the insurance category the prescription falls into and which of Lilly's savings programs, if any, you'd be eligible for.
If you have private insurance, it's worth asking specifically whether you qualify for LillyConnect's copay program, given that its lowest advertised cost applies only to patients with existing private coverage — worth confirming before assuming it applies to your situation. If you don't have private insurance, ask instead about the myMounjaro savings card, which has broader eligibility.
It's also worth asking your prescriber how likely a dose increase is over time, since both products step up in price as the dose tier increases, and budgeting for a potential titration is more realistic than assuming the starting-dose price will hold for the duration of treatment.
If your diagnosis genuinely supports either label, ask your doctor and your insurer, in that order, which pathway gets you the most reliable coverage — since the medication itself won't differ, the label and the paperwork behind it are where the real decision lives.
Frequently asked
- Are Mounjaro and Zepbound literally the same drug?
- Yes, both contain tirzepatide and are manufactured by Eli Lilly. Mounjaro is approved for type 2 diabetes management and Zepbound is approved for chronic weight management, but the active ingredient and injection routine are the same.
- Can I get the $25 copay on Zepbound without private insurance?
- No. Eli Lilly's LillyConnect copay program, which can bring the cost as low as a $25 copay, is only available to patients who already have private insurance coverage. Patients without private insurance would look to the myMounjaro savings card instead, which has different eligibility terms.
- Is Zepbound available at the same pharmacies as Mounjaro?
- Not necessarily yet. Mounjaro has been on the Canadian market longer and is widely stocked. Zepbound was approved in May 2025 and its retail availability is still expanding, so it's worth confirming with a specific pharmacy before assuming it's in stock.